Search alternatives:
nn decrease » _ decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
16 i » 1 i (Expand Search), 16 _ (Expand Search), 10 i (Expand Search)
nn decrease » _ decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
16 i » 1 i (Expand Search), 16 _ (Expand Search), 10 i (Expand Search)
-
801
-
802
-
803
-
804
-
805
-
806
-
807
-
808
-
809
-
810
In patients with Chronic Heart Failure Which Polypharmacy Pheno-groups are associated with adverse health outcomes? (Polypharmacy Pheno-groups and Heart failure outcomes)
Published 2023“…Patient cohorts with excessive polypharmacy (≥9 medications) had the highest probability of survival up to 1.6 years compared to those with lower medication thresholds (≤4); the mortality rate decreased by 18% for patients with excessive polypharmacy [HR=0.82, 95% CI: 0.71 – 0.94]). …”
Get full text
Get full text
Get full text
-
811
-
812
-
813
-
814
-
815
-
816
Methane production enhancement from Tetraselmis biomass co-digestion using frying oil residue as co-substrate and ultrasonication as pretreatment
Published 2023“…Interestingly, compared to untreated Tetraselmis biomass, sonication pretreatment using specific energy of 1.6 kJ/g VS significantly improved specific methane production by 60.5%. …”
Get full text
Get full text
Get full text
-
817
Methane production enhancement from Tetraselmis biomass co-digestion using frying oil residue as co-substrate and ultrasonication as pretreatment
Published 2023“…Interestingly, compared to untreated Tetraselmis biomass, sonication pretreatment using specific energy of 1.6 kJ/g VS significantly improved specific methane production by 60.5%. …”
Get full text
Get full text
Get full text
article -
818
-
819
-
820
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus
Published 2023“…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …”
Get full text
Get full text
Get full text